Abstract
The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Dowsett, M., Harris, A., Stuart-Harris, R. et al. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer 52, 525–529 (1985). https://doi.org/10.1038/bjc.1985.223
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.223
This article is cited by
-
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
Breast Cancer Research and Treatment (1995)
-
First generation aromatase inhibitors ? aminoglutethimide and testololactone
Breast Cancer Research and Treatment (1994)
-
P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine a containing protocols
Medical Oncology and Tumor Pharmacotherapy (1992)
-
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
Breast Cancer Research and Treatment (1992)
-
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications
Cancer Chemotherapy and Pharmacology (1990)